NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis $3.94 -0.07 (-1.62%) Closing price 03:59 PM EasternExtended Trading$3.94 0.00 (0.00%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vanda Pharmaceuticals Stock (NASDAQ:VNDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vanda Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.92▼$4.1150-Day Range$4.01▼$5.5752-Week Range$3.88▼$9.94Volume654,245 shsAverage Volume1.49 million shsMarket Capitalization$238.51 millionP/E RatioN/ADividend YieldN/APrice Target$13.08Consensus RatingHold Company Overview Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, D.C., the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets. Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome. The company also markets Fanapt (iloperidone), an atypical antipsychotic used to treat schizophrenia in adults and approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. In addition to its commercial products, Vanda has pursued clinical development programs addressing disorders such as gastroparesis and other conditions involving sleep, circadian rhythms and the central nervous system. The company’s strategy centers on advancing therapies through clinical development and regulatory review while expanding the use of its approved medicines.AI Generated. May Contain Errors. Read More Vanda Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreVNDA MarketRank™: 2.970203586355 of 5 starsVanda Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 353rd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingVanda Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialVanda Pharmaceuticals has a consensus price target of $13.08, representing about 232.5% upside from its current price of $3.94.Amount of Analyst CoverageVanda Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vanda Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($3.02) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vanda Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.51% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 6.45.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently decreased by 7.81%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Vanda Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.70% of the stock of Vanda Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VNDA Stock News HeadlinesVanda Pharmaceuticals (VNDA) Set to Post Earnings on WednesdayOctober 23 at 2:10 AM | americanbankingnews.comVanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026October 21, 2026 | prnewswire.comElon Musk… A Total Fraud?Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, just got inside Elon Musk's new Cybercab, a vehicle with no steering wheel or pedals. In 2018, the New York Post called Musk a total fraud. Brown's latest footage shows just how far that technology has come since then.October 26 at 1:00 AM | Brownstone Research (Ad)Vanda Pharmaceuticals: Cash Is Running Out Faster Than The LaunchesOctober 15, 2026 | seekingalpha.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramOctober 15, 2026 | finanznachrichten.deVanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary EndpointOctober 15, 2026 | benzinga.comVanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary EndpointOctober 15, 2026 | benzinga.comVanda Pharmaceuticals stock falls after anxiety drug trial failsOctober 14, 2026 | finance.yahoo.comSee More Headlines VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed this year? Vanda Pharmaceuticals' stock was trading at $8.82 at the beginning of 2026. Since then, VNDA shares have decreased by 55.4% and is now trading at $3.9350. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.46. The biopharmaceutical company had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.93 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 49.81% and a negative net margin of 127.41%. Read the conference call transcript. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Intel (INTC), Palantir Technologies (PLTR), Chevron (CVX) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings8/05/2026Today10/26/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 VNDA's financial health is in the Red zone, according to TradeSmith. VNDA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VNDA CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees533Year Founded2002Price Target and Rating Average Price Target for Vanda Pharmaceuticals$13.08 High Price Target$20.00 Low Price Target$7.50 Potential Upside/Downside+231.6%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$220.47 million Net Margins-127.41% Pretax Margin-82.14% Return on Equity-49.81% Return on Assets-33.29% Debt Debt-to-Equity Ratio0.01 Current Ratio1.61 Quick Ratio1.60 Sales & Book Value Annual Sales$216.10 million Price / Sales1.10 Cash FlowN/A Price / Cash FlowN/A Book Value$5.54 per share Price / Book0.71Miscellaneous Outstanding Shares60,460,000Free Float53,993,000Market Cap$238.51 million OptionableOptionable Beta0.69 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:VNDA) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredNNVC Is Heating Up as Its Antiviral Pipeline Advances!NanoViricides (NYSE American: NNVC) is advancing NV-387, a broad-spectrum antiviral candidate, into Phase II t...Equiscreen | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredElon Musk… A Total Fraud?Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, ju...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
